SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 2003
Commission file number 0-17449
PROCYON CORPORATION
--------------------------------------------
(Name of small business issuer in its charter)
Colorado 59-3280822
---------------------- ----------------------
(State of incorporation) (I.R.S. Employer ID No.)
1150 Cleveland Street, Suite 410,
Clearwater, Florida 33755
-------------------------------------- --------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code: (727) 447-2998
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to section 12(g) of the Act:
Common Stock
[X] Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
[ ] Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrants knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB.
Revenues for the fiscal year ended June 30, 2003: $1,645,759
The aggregate market value of the 3,726,188 shares of Common Stock held by
non-affiliates was $1,583,629 on September 24, 2003 based on the average bid and
asked price of $.425 on such date. As of September 24, 2003, 8,042,388 shares of
the issuers Common Stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE:
The information required by Part III of this annual report is incorporated by
reference from the registrants' definitive proxy statement to be filed with the
Commission on or before October 28, 2003. If such proxy statement is not filed
by such date, the information required by Part III of this annual report will be
filed with the Commission as an amendment to this Form 10-KSB under cover of
Form 10-KSB/A, not later than October 28, 2003.
Transitional Small Business Disclosure Format: Yes No X
INDEX
Title Page
ITEM 1.DESCRIPTION OF BUSINESS............................................3
ITEM 2.DESCRIPTION OF PROPERTY............................................8
ITEM 3.LEGAL PROCEEDINGS..................................................8
ITEM 4.SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS................8
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS..........8
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.........10
ITEM 7. FINANCIAL STATEMENTS..............................................14
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE.............................................14
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT....................15
ITEM 10. EXECUTIVE COMPENSATION...........................................15
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT...........................................................15
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS...................15
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.................................15
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES...........................16
Part I
ITEM 1. BUSINESS
History and Organization
Procyon Corporation (the "Company"), a Colorado corporation, was
incorporated on March 19, 1987 and was deemed a development stage company until
May 1996 when it acquired Amerx Health Care Corp. ("Amerx"), a corporation based
in Clearwater, Florida, which was wholly owned by John C. Anderson. Amerx
develops and markets proprietary medical products used in the treatment of
pressure ulcers, dermatitis, inflammation, and other skin problems. Sirius
Medical Supply, Inc. ("Sirius"), a Florida corporation, was formed in 2000 to
operate as a full service mail order medical supply company selling primarily to
Medicare and Medicaid customers. Amerx and Sirius are wholly owned subsidiaries
of Procyon Corporation. Historically, Amerx's products have been sold through
distributors to health care institutions, such as physicians, nursing homes and
home health care agencies, and to retailers, including national and regional
chain stores and pharmacies, while Sirius's products are sold directly to
Medicare and Medicaid patients.
Products
Amerx's products currently consist of AmeriGel(R) Hydrogel Wound Dressing,
AmeriGel(R) Preventive Care Lotion, AmeriGel(R) Preventive Barrier Lotion, and
AmeriGel(R) Saline Wound Wash. The AmeriGel(R) Hydrogel Wound Dressing is now
formulated to be used as a wound dressing to manage pressure ulcers stages I-IV,
stasis ulcers, diabetic skin ulcers, post surgical incisions, cuts, abrasions,
1st and 2nd degree burns, and skin irritations. The AmeriGel(R) Preventive Care
Lotion has emollients, which restore moisture to fragile skin, protect the skin
against tears and chafing, and assist in prevention of chronic pressure ulcers.
The AmeriGel(R) Barrier Lotion provides barrier protection to reduce the harmful
effects of urine and feces in incontinent patients. The AmeriGel(R) Saline Wound
Wash was introduced as a wound cleanser that contains saline and Oakin. The
industry standard for wound cleansing has been saline, since tap water has
chemicals and additives that can potentially be harmful to a chronic wound.
Amerx introduced no new products to the market in fiscal 2003,
concentrating efforts on market penetration of the current product line.
However, development of two-inch and four-inch gauze sponges saturated with
AmeriGel(R) Hydrogel Wound Dressing progressed to the point that the company
feels that this product can be introduced to the market in fiscal 2004 through
current cash flow. Manufacturing sources for this product addition have been
identified and the company is currently in the process of obtaining approval of
the reimbursement code and subsequent registration with the Food & Drug
Administration ("FDA").
Management also feels a market exists in the application of its
formulations in the dermatology field. Preliminary due-diligence with
professionals in that field have occurred with the concentration on the proposed
development of an acne cream and facial scrub. The funds necessary for the
development of this potential product line have not been identified but are
being pursued by management. The Company has not expended any funds towards
research and development efforts during fiscal year ended June 30, 2003.
-3-
Management believes that each Amerx product is based on proprietary
formulations, which the Company protects as trade secret information. Each
product is registered with the Food and Drug Administration and receives a
National Drug Code.
In the United States, the Company sells its products to nursing homes,
hospitals, home healthcare agencies, retail and "closed door" pharmacies and
similar institutions. The patients at these institutions for whose care the
Company's products are purchased often are covered by medical insurance.
Accordingly, the Company's customers routinely seek reimbursement for the cost
of the Company's products from third party payers such as Medicare, Medicaid,
health maintenance organizations and private insurers. The availability of
reimbursement from such third party payers is a factor in the Company's sales of
its products. In June 2002, the Company was granted a Medicare Part B HCPCS
Reimbursement Code ("Reimbursement Code") for its AmeriGel(R) Hydrogel Wound
Dressing, which allows it to qualify for Medicare reimbursements. The
Reimbursement Code granted to Amerx was the highest and fullest reimbursement
allowed for such products, and was obtained as a result of significant time and
effort. With this Reimbursement Code, Amerx expects to reintroduce itself to the
institutional market place, such as to nursing homes and health care agencies.
The AmeriGel(R) Preventive Care Lotion and the AmeriGel(R) Barrier Lotion are
not eligible for Medicare Part B reimbursement as they are formulated for
preventive maintenance care and as a skin protectant. During fiscal 2003, sales
of the Company's skin and wound care products represented approximately 82% of
net sales by the Company, while sales of the Company's diabetic products
represented approximately 18% of net sales. Medicare and Medicaid do not
reimburse Amerx directly for their sales to these pharmacies and institutions.
However, Medicare and Medicaid reimbursements made directly to Sirius account
for approximately 80% of Sirius's sales. Approximately 20% of Sirius's sales are
comprised of secondary insurance payments and payments from individual
customers.
Sirius's products at this time consist primarily of diabetic supplies,
glucose monitors, test strips, lancets, and syringes. Sirius added heating pads
to its inventory at the end of the fiscal year and will continue to add items to
sell to reach its goal of being a full service mail order medical supply
company. Sirius continues to build its customer base with advertisements and
referrals and continually tests new methods for reaching new prospective
customers. Sirius also has a website (WWW.SIRIUSMEDICAL.COM) to help reach new
prospective customers that might want to reach the company via the Internet.
Market for Products
The institutional market for skin and wound care treatment products is
comprised of hospitals, nursing homes, home health care agencies and other
health care institutions that provide wound care to a large number of patients.
Management believes that AmeriGel(R) products represent an inexpensive, yet
effective, treatment and prevention program for chronic pressure ulcers and
other skin problems, which are treated in health care institutions. Management
believes that obtaining the Reimbursement Code will enhance Amerx's ability to
offer AmeriGel(R) Hydrogel Wound Dressing to institutional entities, and intends
to focus more resources in fiscal 2004 to this market.
The retail market for skin care and wound care products is comprised mainly
of national & regional chain stores, and pharmacies that sell such products to
individuals for personal use outside of health care facilities. The Company's
products are presently sold retail in independent pharmacies. The Company
initiated a direct response program and is now making direct retail sales to
individual consumers nationally.
-4-
The market for Sirius's products is comprised of diabetic patients who
receive benefits from Medicare or Medicaid, or from their insurance companies.
Sirius attracts these customers through advertising and direct marketing.
Distribution and Sales
The Company's traditional method of distribution has been through retail
distributors. Management expects to continue increasing its distributor base,
particularly with distributors with an ability to introduce the Company's
products in new geographical areas and to new retail chains. Distributors
typically purchase products from the Company on standard credit terms. The
Company supports its distributors through product literature, advertising and
limited participation at industry trade shows. All existing distributors sell
Amerx products on a non-exclusive basis. Amerx uses other marketing channels
that include direct response, trade publications, and physician referral's to
attract it's customer base.
Sirius's channel of distribution is by mail order direct to consumers. The
Company has attracted and retained customers through its direct response
marketing efforts, this is the only method used by Sirius to attract customers.
Sirius intends to test new marketing channels in fiscal 2004. Sirius's customer
base is growing and has more than doubled in the last fiscal year. The Company
believes it has substantial potential as the market contains over 17 million
diabetics in the United States, and is growing, according to the American
Diabetes Association.
The Company periodically has received inquiries about foreign market
distribution. These inquiries have been generated by the Company's advertising,
market presence and web sites (WWW.AMERXHC.COM and WWW.AMERIGEL.COM). The
Company intends to respond to and pursue all such inquiries.
Significant Customers
Amerx's customer base has become more diversified over the past two years.
Management believes that, while any customer loss is not beneficial to the
Company, no single customer accounts for over 5% of the Company's gross sales.
The Company has been able to maintain relationships with its distributors and
has been able to establish relationships with a few new distributors each year.
Sirius's customer base has no significant customers as they deal with end users
and no one end user accounts for more than .01% of the Company's gross sales.
Manufacturing
During fiscal 2003, manufacturing of all of Amerx's products was completed
by a small regional company, which has in the past performed, and will in the
future perform, research and development activities for Amerx. Amerx does not
have a written contract with this manufacturer and there are no minimum purchase
agreements. Management believes there are other companies that could manufacture
Amerx's products according to their specifications, if necessary. The sudden
loss or failure of this manufacturer could significantly impair Amerx's ability
to fulfill customer orders on a short-term basis and therefore, could materially
and adversely affect the Company's operations. However, management does not see
this as an issue as management as been able to keep a good relationship with the
manufacturer, and does not foresee that changing in the future.
-5-
Amerx's manufacturing and packaging activities are performed pursuant to
current good manufacturing practices ("CGMP") as defined under the United States
Federal Food, Drug and Cosmetic Act, as amended (the AAct@), and the regulations
promulgated under the Act. All manufacturing activities are required to comply
with the product specifications, supplies and test methods developed by Amerx
specifically for its products, as well as the CGMP, which apply to all
activities conducted by the manufacturer in the facility.
A single supplier furnishes one proprietary ingredient contained in all of
Amerx's products. Amerx does not have a written contract with the supplier of
this ingredient and management believes that an alternative supplier could be
secured within a reasonable period of time. The manufacturer generally provides
other raw materials and ingredients and management believes there are multiple
suppliers of these materials and ingredients. However, there can be no assurance
that Amerx would be able to timely secure an alternative supplier and the
failure to replace a supplier in a timely manner could materially harm Amerx's
operations. Once again management does not see this as an obstacle as good
working relationships have been established with the vendor.
Sirius purchases its products from several different medical companies
either on a direct basis, or through medical distributors. The company carries
most every major brand of diabetic testing products as well as some off brand
diabetic testing products. Management feels that if adverse economic conditions
occurred for one or more of its suppliers, that this effect would not have a
significant effect on Sirius, as there are other supply channels to purchase
from, as well as an assortment of products to purchase that achieve the same
goal.
Proprietary Rights
In January 1999, the United States Patent and Trademark Office registered
the Company's AmeriGel(R) trademark. Amerx has made a trademark application for
the principal proprietary ingredient used in all of its currently available
products. Amerx relies on a combination of trademark and trade secret protection
and confidentiality agreements to establish and protect its proprietary rights.
Competition
The market for skin and wound care treatment products is highly competitive
and fragmented. Competition is intense and is based primarily on product
efficacy, brand recognition, loyalty, quality, price and availability of shelf
space in the retail market. The Company competes against several large
well-capitalized companies offering a broad range of skin treatment products as
well as numerous small competitors having a limited number of products. Many of
these competitors have longer operating histories, better name recognition and
greater financial, marketing and other resources than the Company. Because of
the intense competition and the Company's financial condition, there can be no
assurance that it will be able to increase its market share.
-6-
The market for diabetic supplies is also highly competitive, and Sirius
will compete with other large companies for market share. Sirius can compete on
the same level as these other companies as to product offerings. However, until
Sirius's customer base grows, other larger companies will benefit from volume
discounts on purchases etc, that Sirius has yet to benefit from. Management
believes Sirius's success will hinge on customer service rather than product
margin, and with time Sirius will benefit from the same volume discounts enjoyed
by larger companies.
Governmental Approvals and Regulations
The production and marketing of the Company's products are subject to
regulation for safety, efficacy and quality by numerous governmental authorities
in the United States. Amerx's advertising and sales practices are subject to
regulation by the Federal Trade Commission (the "FTC"), the FDA and state
agencies. The Federal Food, Drug and Cosmetic Act, as amended (the "FFDC Act"),
the regulations promulgated thereunder, and other federal and state statutes and
regulations govern, among other things, the testing, manufacture, safety,
effectiveness, labeling, storage, record keeping, approval, advertising and
promotion of Amerx's products. The Food and Drug Administration regulates the
contents, labeling and advertising of many of Amerx's products. Amerx may be
required to obtain approval for proposed nonprescription products. This
procedure involves extensive clinical research, and separate FDA approvals are
required at various stages of product development. The approval process
requires, among other things, presentation of substantial evidence to the FDA,
based on clinical studies, as to the safety and efficacy of the proposed
product. After approval, manufacturers must continue to expend time, money and
effort in production and quality control to assure continual compliance with the
current Good Manufacturing Practices regulations.
Certain of Amerx's wound and skin care products are registered with the FDA
as "devices" pursuant to the regulations under Section 510(k) of the FFDC Act. A
device is a product used for a particular medical purpose, such as to cover a
wound, with respect to which no pharmacological claim can be made. A device
which is "substantially equivalent" to another device existing in the market
prior to May 1976 can be registered with the FDA under Section 510(k) and
marketed without further testing. Amerx currently markets one product which
qualifies as a medical device.
Sirius's advertising and sales practices are subject to regulation by the
Federal Trade Commission (the "FTC"), Medicare, and state Medicaid agencies. FDA
approvals for its products are, handled by the respective manufactures. Medicare
and Medicaid regulate advertising, sales pricing, and the guidelines under which
Sirius operates.
The Company believes that it is in compliance with all applicable laws and
regulations relating to its operations. Compliance with the provisions of
national, state and local environmental laws and regulations has not had a
material adverse effect upon the capital expenditures, earnings, financial
position, liquidity or competitive position of the Company.
Employees
As of September 1, 2003, the Company had a total of 13 employees, 12
full-time employees, consisting of 3 management employees, 6 sales-related
employees, 3 administrative employees, and 1 part- time employee.
-7-
ITEM 2. PROPERTIES
The Company currently maintains its offices at 1150 Cleveland Street, Suite
410, Clearwater, Florida 33755. The Company's offices consist of approximately
3,536 square feet of space, which is leased from an unrelated party. Management
believes the facility is adequate for the Company's current needs. However,
management is looking to relocate the office in fiscal 2004.
ITEM 3. LEGAL PROCEEDINGS
The Company is not a party to any pending material legal proceedings
nor is its property the subject of a pending legal proceeding.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
Part II
ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY AND RELATED STOCK
MATTERS.
Since October 1996, the Company's Common Stock has traded on the OTC
Bulletin Board, an electronic quotation system used by members of the National
Association of Securities Dealers, Inc. The following table sets forth for each
period indicated the high and low closing bid prices for the Common Stock, as
reported by National Quotation Bureau, LLC. Bid quotations reflect inter-dealer
quotations, without retail markups, markdowns or commissions, and do not
necessarily reflect actual transactions.
Fiscal 2002 HIGH LOW
First Quarter.............................. $ .5000 $ .2000
Second Quarter............................. .2000 .0600
Third Quarter.............................. .2500 .0600
Fourth Quarter............................. .7500 .2500
Fiscal 2003 HIGH LOW
First Quarter.............................. $ .9000 $ .5700
Second Quarter............................. .8500 .3000
Third Quarter.............................. .7500 .3000
Fourth Quarter............................. 1.000 .2500
As of September 24, 2003, there were approximately 163 record holders of
the Company's Common Stock. On September 23, 2003, the closing bid price of the
Company's common stock was $.40 and the closing ask price was $.45. On September
23, 2003, the last date on which a sale occurred, the last reported sale price
was $.45.
Holders of Common Stock are entitled to receive such dividends if declared
by the Company's Board of Directors. The Company has declared no dividends on
the Common Stock.
-8-
Holders of the Series A Convertible Preferred Stock are entitled to
receive, if declared by the Board of Directors, quarterly dividends at an annual
rate of $.10 per share. Dividends accrue without interest, from the date of
issuance, and are payable in arrears in cash or common stock, when and if
declared by the Board of Directors. No dividends had been declared or paid at
June 30, 2003, and dividends if ever declared, in arrears at such date total
approximately $141,511.
Holders of the Preferred Stock have the right to convert their shares of
Preferred Stock into an equal number of shares of Common Stock of the Company.
Such shares will automatically convert into one share of Common Stock at the
close of a public offering of Common Stock by the Company provided the Company
receives gross proceeds of at least $1,000,000, and the initial offering price
of the Common Stock sold in such offering is equal to or in excess of $1 per
share. During fiscal 2003, holders of 57,500 shares of Preferred Stock converted
their shares to 57,500 shares of Common Stock.
As reflected in the price quotations above, there have been significant
price fluctuations in the Company's Common Stock. Factors that may have caused
or can cause market prices to fluctuate include the number of shares available
in the public float, any purchase or sale of a significant number of shares
during a relatively short time period, quarterly fluctuations in results of
operations, issuance of additional securities, entrance of such securities into
the public float, market conditions specific to the Company's industry and
market conditions in general, and the willingness of broker-dealers to effect
transactions in low priced securities. In addition, the stock market in general
has experienced significant price and volume fluctuations in recent years. These
fluctuations, which may be unrelated to a Company's operating performance, have
had a substantial effect on the market price for many small capitalization
companies such as the Company. Factors such as those cited above, as well as
other factors that may be unrelated to the operating performance of the Company,
may significantly affect the price of the Common Stock.
Equity Compensation Plan Information
The following table contains information regarding Procyon's equity
compensation plan as of June 30, 2003. The only equity compensation plan
maintained by Procyon is the company's Omnibus Stock Option plan (the "Option
Plan"). The Option Plan was approved by the shareholders of Procyon in 1998.
Plan Category Number of Securities Weighted-average Number of securities
to be issued upon exercise price of remaining available for
exercise of outstanding options, future issuance under
outstanding options, warrants and rights equity compensation
warrants and rights plans (excluding
securities reflected in
column (a))
( a ) ( b )
( c )
Equity compensation
plans approved by 300,000* $0.20 603,500*
security holders
Equity compensation
plans not approved by 0 0 0
security holders
-------------------- ---------------- ---------------------
Total 300,000 $0.20 603,500
==================== ================ =====================
-9-
* 96,500 options were issued and exercised during fiscal 2003 and are no
longer outstanding.
1. The total number of securities to be issued upon exercise of outstanding
options, warrants and rights consists of options for the purchase of
Procyon common stock issued pursuant to the Option Plan to employees,
officers, directors and consultants. The total number of securities to be
issued upon exercise of the options is stated, regardless of whether the
options are currently vested.
2. The outstanding options issued under the Option Plan range in exercise
price from $0.15 to $0.25 per share.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
The Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995
This Report on Form 10-KSB, including Management's Discussion and Analysis
or Plan of Operation, contains forward-looking statements. When used in this
report, the words "may," "will," "expect," "anticipate," "continue," "estimate,"
"project," "intend," "believe" and similar expressions, variations of these
words or the negative of those word are intended to identify forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 regarding events, conditions
and financial trends including, without limitation, business conditions in the
skin and wound care market and the general economy, competitive factors, changes
in product mix, production delays, manufacturing capabilities, and other risks
or uncertainties detailed in other of the Company's Securities and Exchange
Commission filings. Such statements are based on management's current
expectations and are subject to risks, uncertainties and assumptions. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, the Company's actual plan of operations, business
strategy, operating results and financial position could differ materially from
those expressed in, or implied by, such forward-looking statements.
The Company's business in general is subject to certain risks including but
not limited to the following, availability to produce or obtain, or have to pay
excessive prices for, the raw materials it needs, the Company may not be able to
use its tax loss carry forwards before they expire, that the Company' s
outsourced manufacturing facilities may be inadequate to meet demand, that
competitive pressures may require the Company to lower prices of its products,
that new products may not receive required approvals by government agencies, and
that the Company may not be able to obtain financing when needed.
-10-
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company's condensed financial statements have been prepared in
accordance with accounting principles generally accepted in the United States of
America, which require the Company to make estimates and judgments that affect
the reported amounts of assets, liabilities, revenues and expenses, and the
related disclosures. A summary of those significant accounting policies can be
found in the Notes to the Consolidated Financial Statements included in this
annual report. The estimates used by management are based upon the Company's
historical experiences combined with management's understanding of current facts
and circumstances. Certain of the Company's accounting policies are considered
critical as they are both important to the portrayal of the Company's financial
condition and the results of its operations and require significant or complex
judgments on the part of management. Management believes that the following
represent the critical accounting policies of the Company: advertising and
marketing, and stock based compensation.
Advertising and Marketing
Currently most of the Company's advertising is direct response. The Company
recognizes expenses from direct response advertising as incurred because
insufficient historical data exists. Sirius's management feels additional
historical data is necessary to consider changing this policy. Amerx's
management feels this policy may never change due to the nature of the customer
base and the product lines currently sold.
Stock Based Compensation
Statement of Financial Accounting Standard ("SFAS") No 123, defines the
fair-value based method of accounting for stock-based employee compensation
plans and transactions in which an entity issues its equity instruments to
acquire goods or services from non-employees. SFAS No 123 encourages but does
not require companies to record compensation cost for stock-based employee
compensation plans at fair value. We have chosen to account for employee
stock-based compensation plans using the intrinsic-value method prescribed in
Accounting Principles Board Opinion No. 25. Accordingly, employee compensation
cost for stock is measured as the excess, if any, of the estimated fair value of
our stock at the date of the grant over the amount an employee must pay to
acquire the stock.
General
The continuing operations and revenues of the Company consist of the
operations of and revenues generated by Amerx and Sirius, the Company's two
wholly owned subsidiaries. Amerx's wound care and skin care products, marketed
under the trademark AmeriGel(R) , are formulated to enhance the quality of skin
and wound care and to lower the treatment cost of those who suffer from wound
and skin care problems. Sirius markets and distributes diabetic supplies via
mail order.
Amerx markets AmeriGel(R) products to institutional customers such as
nursing homes, hospitals and home health agencies and to retail customers.
Institutional sales are made either directly to the end user or through medical
supply distributors. Many institutional customers will not purchase directly
from the manufacturer; they will purchase products only through a national
distributor who warehouses the products and supplies the products directly to
the customer. Accordingly, the Company's products must be in the distributor's
warehouse in order for the Company to compete with other manufacturers. Amerx
reaches the retail consumer primarily through distributors, but in some cases,
-11-
through direct sales to a retail store chain. Amerx's skin care products were
being distributed to institutions and to retail stores through McKesson Drug,
AmeriSource/Bergen Brunswig, Cardinal Health, Bindley Western Drug and a number
of smaller local and regional distributors.
Future Developments
Amerx will continue to seek further penetration of the podiatric market
through its' participation in industry trade shows, advertisements in trade
journals, development of additional distributor relationships, opening new
geographical territories (including foreign markets), and coordinating with
physicians and educational institutions to provide training to the wound care
professional. Amerx management seeks to develop new products for this market as
a need becomes evident through its association with health care professionals.
Amerx intends to pursue potential product developments in other medical
disciplines including dermatology, veterinary care and other wound care
applications. Preliminary investigations of these aforementioned markets are
ongoing. Management will pursue increased marketing efforts in the institutional
wound care market as a result of the Amerigel Hydrogel Wound Dressing being
granted a Medicare HCPCS Reimbursement Code.
Sirius will aggressively attempt to add to its current customer base
through the use of advertising, direct physician contact, referrals and possible
acquisition of similar business entities. Product lines will be increased as
customer needs dictate and economics allow.
Results of Operations
Comparison of Fiscal 2003 & 2002. Net sales during fiscal 2003 were
approximately $1,646,000 as compared to approximately $1,358,000 in fiscal 2002,
an increase of approximately $288,000, or 21%. Management believes that this
increase is attributable to its continuing marketing efforts, and growth of its
customer base. Sales growth in Sirius and Amerx was 86%, and 13% respectively
over the previous year. Sirius customer base doubled over the fiscal 2003
period, while Amerx shifted it resources away from the direct response retail
market to pursue the physician market. Amerx is having success in this new
market and hopes to capture more of the physician market in fiscal 2004.
Cost of sales increased, to approximately $364,000 in fiscal 2003 as
compared to approximately $263,000 in fiscal 2002. Cost of sales rose
approximately 3% over the previous year relative to sales. This increase is
primarily attributable to Sirius's increase in sales with less gross profit
margin involved in its product sales. However, Sirius hopes to start realizing
better volume discounts in fiscal 2004. Amerx's costs have remained consistent
over the past year with only a slight increase in some of its raw materials and
packaging.
Gross profit increased to approximately $1,282,000 during fiscal 2003 as
compared to approximately $1,096,000 during fiscal 2002, an increase of about
$186,000, or 17%. As a percentage of sales, gross profit was 78% in fiscal 2003,
as compared to 81% in fiscal 2002.
-12-
Operating expenses during fiscal 2003 were approximately $1,208,000,
consisting of approximately $560,000 in salaries and benefits, $648,000 in
selling, general and administrative expenses. This represents an increase in
expenses of approximately $11,000 as compared to expenses in fiscal 2002.
Expenses in fiscal 2002 consisted of $457,000 in salaries and benefits, and
$740,000 in selling, general and administrative expenses. During fiscal 2003,
the substantial increase in salaries and benefits was caused primarily by the
Company's shift toward commission based, compensation as well as the restocking
of the employee base that was depleted due to economic conditions caused by the
events of September 11, 2001. Selling, general and administrative expenses were
reduced in large part as Amerx moved away from the retail side of marketing and
the high cost of advertising associated with it. As a percentage of net sales,
operating expenses during fiscal 2003 decreased to 73%, as compared to 88%
during fiscal 2002, as net sales increased $288,000 for the year on only an
$11,000 increase in expenses.
Profit from operations increased to approximately $73,000 in 2003, as
compared to a loss from operations of approximately $101,000 in fiscal 2002. Net
Profit (after dividend requirements for Preferred Shares) was approximately
$38,000 during fiscal 2003, compared to a net loss of approximately $167,000
during fiscal 2002.
As of June 30, 2003, the Company had a deferred tax asset of approximately
$988,000, consisting primarily of the tax benefit of net operating loss
carryforward. The Company recorded a valuation allowance equal to 100 percent of
the deferred tax asset, as the Company determined that it was more likely than
not the deferred tax asset will be realized. The valuation allowance decreased
approximately $416,000 from fiscal 2002 to 2003.
Liquidity and Capital Resources
Historically, the Company has financed its operations through a combination
of revenues from operations, shareholder loans, and the public sales of equity.
As of June 30, 2003, the Company's principal sources of liquidity included
inventories of approximately $97,000, and net accounts receivable of
approximately $148,000. The Company had negative working capital of
approximately $268,000 and long- term debt of approximately $21,000 at June 30,
2003.
Operating activities used cash of approximately $37,000 during fiscal 2003
and approximately $217,000 during fiscal 2002, consisting primarily of an
increase in receivables of approximately $50,000 and net losses of $138,000,
respectively. Cash used in investing activities during fiscal 2003 and 2002 was
approximately $1,000 and $7,000, respectively. Cash provided by financing
activities during fiscal 2003 and 2002 was approximately $80,000 and $205,000,
respectively.
During fiscal 2003, holders of 57,500 shares of Preferred Stock converted
their shares to Common Stock.
Commitments of Capital Expenditures
At June 30, 2003 the Company had commitments for capital expenditures of
$19,000 related to office equipment, as well as a commitment to purchase new
equipment for Amerx's product manufacturing needs for approximately $16,000.
-13-
ITEM 7. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Consolidated financial statements as of June 30, 2003, and 2002 were
audited by Ferlita, Walsh & Gonzalez P.A., the Company's independent auditors,
as indicated in their report included appearing at page F-1.
INDEX TO FINANCIAL STATEMENTS
-----------------------
Page
Report of Independent Certified Public Accountants.......................... F-1
Consolidated Balance Sheet June 30, 2003.................................... F-2
Consolidated Statements of Operations For the Years
Ended June 30, 2003 and 2002............................................... F-3
Consolidated Statements of Stockholders' Deficiency For the Years
Ended June 30, 2003 and 2002............................................... F-4
Consolidated Statements of Cash Flows For the Years Ended
June 30, 2003 and 2002..................................................... F-5
Notes to Consolidated Financial Statements.................................. F-6
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE.
During the two preceding fiscal years, there were no disagreements with
the Company's auditors on any matters of accounting principles or practices,
financial statement disclosure, or auditing scope of procedure that would have
caused the Company's accountants to make reference to such agreements in
connection with their report.
ITEM 8A. CONTROLS AND PROCEDURES.
Management of the Company, with the participation of the Chief Executive
Officer and the Chief Financial Officer, has conducted an evaluation of the
effectiveness of the Company's disclosure controls and procedures pursuant to
Rule 13a-15 under the Securities Exchange Act of 1934 as of the end of the
period covered by this report. Based on that evaluation, management, including
the Chief Executive Officer and Chief Financial Officer, has concluded that, as
of the date of this report, the Company's disclosure controls and procedures
were effective in ensuring that all material information relating to the Company
required to be disclosed in this report has been made known to management in a
timely manner and ensuring that this information is recorded, processed,
summarized and reported within the time periods specified in the SEC's rules and
regulations.
During the last quarter of fiscal 2003, the Company did not institute any
significant changes in its internal control over financial reporting that
materially affected or is reasonably likely to materially affect, the Company's
internal control over financial reporting.
-14-
PART III
Certain information required by Part III is omitted from this Report and is
incorporated by reference to information contained in the Company's proxy
statement pursuant to Regulation 14A (the "Proxy Statement") to be filed not
later than 120 days after the end of the fiscal year covered by this report.
Only those sections of the Proxy Statement that specifically address the items
set forth herein are incorporated by reference.
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL
PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT OF
THE REGISTRANT.
The information required by this Item is incorporated by reference to the
information contained in the "Election of Directors" and "Section 16(a)
Beneficial Ownership Reporting Compliance" sections of the Company's Proxy
Statement to be filed with the Securities and Exchange Commission within 120
days after the end of fiscal year ended June 30, 2003.
ITEM 10. EXECUTIVE COMPENSATION.
The information required by this Item is incorporated by reference to the
information contained in the "Executive Compensation" section of the Company's
Proxy Statement to be filed with the Securities and Exchange Commission within
120 days after the end of fiscal year ended June 30, 2003.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT.
The information required by this Item is incorporated by reference to the
information contained in the "Security Ownership of Certain Beneficial Owners
and Management: section of the Company's Proxy Statement to be filed with the
Securities and Exchange Commission within 120 days after the end of fiscal year
ended June 30, 2003.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information required by this Item is incorporated by reference to the
information contained in the "Certain Relationships And Related Transactions"
section of the Company's Proxy Statement to be filed with the Securities and
Exchange Commission within 120 days after the end of fiscal year ended June 30,
2003.
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.
(a)Exhibits
-15-
1. The financial statements filed herewith are listed in the Index to
Financial Statements included in Item 7.
Exhibit No. Document
* 3.1 Articles of Incorporation
+ 3.1.1 Articles of Amendment to Articles of Incorporation
* 3.2 Bylaws
+ 4.1 Designation of Series A Preferred Stock
+ 10.4 Loan and Security Agreement, dated as of January 1, 1995, by
and between the Company and Amerx Health Care Corp.,
including Promissory Notes issued there under.
o 10.4 Agreement and Plan of Exchange, dated January 31, 1996, by
and between the Company and Amerx.
x 31.1 Certification of John C. Anderson pursuant to Exchange Act
Rule 13a- 14(a)/15d-14(a)
x 32.1 Certification Pursuant to 18 U.S.C.ss.1350, as Adopted
Pursuant to Section906 of the Sarbanes-Oxley Act Of 2002
* Incorporated by reference to the Company's Registration Statement on
Form S-1, S.E.C. File No. 33-13273.
+ Incorporated by reference to the Company's Form 10-KSB for the fiscal
year ended June 30, 1995.
o Incorporated by reference to the Company's Form 8-K filed on or about
February 2, 1996.
x Filed herewith.
(b) Reports on Form 8-K
None.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Audit Fees. In fiscal 2002, the Company paid to its independent accountants
$20,272 in fees related directly to the audit and review of the Company's
financial statements. In fiscal 2003, the Company paid to its independent
accountants $32,157 in fees related directly to the audit and review of the
Company's financial statements.
Tax Fees: In fiscal 2002, the Company paid to its independent accountants
$1,000 in fees related directly to tax preparations. In fiscal 2003, the Company
paid to its independent accountants $1,000 in fees related directly to tax
preparations.
All Other Fees: In fiscal 2002, the Company paid to its independent
accountants $750 in fees, the majority of these fees were related to research on
possible acquisitions. The Company's independent accountants performed no other
services for the Company during fiscal 2003 other than the audit services
described above.
-16-
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, there unto duly authorized.
PROCYON CORPORATION
By: /s/ John C. Anderson
-------------------------------
John C. Anderson,
President and acting
Principal Executive,
Financial and Accounting
Officer
Date: September 24, 2003
Pursuant to the requirements of the Securities Exchange Act of 1934, the
following persons on behalf of the registrant and in the capacities and on the
dates indicated have signed this report below.
Signature Title Date
--------- ----- ----
/s/ John C. Anderson President and Acting 9/25/03
----------------------------- Principal Executive, Financial
John C. Anderson and Accounting Officer
/s/ Chester L. Wallack Director 9/25/03
-----------------------------
Chester L. Wallack
/s/ Fred W. Suggs, Jr. Director 9/26/03
-----------------------------
Fred W. Suggs, Jr.
/s/ Alan B. Crane Director 9/26/03
-----------------------------
Alan B. Crane
/s/ Richard T. Thompson Director 9/26/03
-----------------------------
Richard T. Thompson
/s/ Jeffery S. Slowgrove Director 9/28/03
-----------------------------
Jeffery S. Slowgrove
-17-
EXHIBIT INDEX
Exhibit No. Document Item No.
* 3.1 Articles of Incorporation 3
+ 3.1.1 Articles of Amendment to Articles of Incorporation 3
* 3.2 Bylaws 3
+ 4.1 Designation of Series A Preferred Stock 4
+ 10.4 Loan and Security Agreement, dated as of
January 1, 1995, by and between the Company and
Amerx Health Care Corp., including Promissory Notes
issued there under. 10
o 10.4 Agreement and Plan of Exchange, dated January 31,
1996, by and between the Company and Amerx.
x 31.1 Certification of John C. Anderson pursuant to
Exchange Act Rule 13a- 14(a)/15d-14(a)
x 32.1 Certification Pursuant to 18 U.S.C.ss.1350, as
Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act Of 2002
* Incorporated by reference to the Company's Registration
Statement on Form S-1, S.E.C. File No. 33-13273.
+ Incorporated by reference to the Company's Form 10-KSB
for the fiscal year ended June 30, 1995.
o Incorporated by reference to the Company's Form 8-K filed on
or about February 2, 1996.
x Filed herewith.
-18-
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
Years Ended June 30, 2003 and 2002
TABLE OF CONTENTS
Page No.
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS........................F-1
FINANCIAL STATEMENTS
Consolidated Balance Sheet..............................................F-2
Consolidated Statements of Operations...................................F-3
Consolidated Statements of Stockholders' Deficiency.....................F-4
Consolidated Statements of Cash Flows...................................F-5
Notes to Financial Statements...........................................F-6
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors
Procyon Corporation and Subsidiaries
Clearwater, Florida
We have audited the accompanying consolidated balance sheet of Procyon
Corporation and Subsidiaries as of June 30, 2003 and the related statements of
operations, stockholders' deficiency, and cash flows for the years ended June
30, 2003 and 2002. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Procyon Corporation and
Subsidiaries as of June 30, 2003 and the results of its operations and its cash
flows for the years ended June 30, 2003 and 2002, in conformity with accounting
principles generally accepted in the United States of America.
/s/ FERLITA, WALSH & GONZALEZ, P.A.
------------------------------------
FERLITA, WALSH & GONZALEZ, P.A.
Certified Public Accountants
Tampa, Florida
August 11, 2003
F-1
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
June 30, 2003
ASSETS
CURRENT ASSETS
Cash $ 41,549
Accounts receivable, less allowance
of $20,500 for doubtful accounts 148,052
Prepaid expenses 28,265
Inventories 96,522
-----------
TOTAL CURRENT ASSETS 314,388
PROPERTY AND EQUIPMENT
Office equipment 85,884
Furniture and fixtures 15,164
Production equipment 14,236
-----------
115,284
Accumulated depreciation (66,155)
-----------
49,129
OTHER ASSETS
Deposits 844
Certificates of deposit, restricted 17,114
-----------
17,958
-----------
$ 381,475
===========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Current portion of long-term note payable to stockholder 6,319
Current portion of capital lease obligations 8,202
Accounts payable 208,111
Accrued expenses 67,402
Note payable to stockholder 291,488
-----------
TOTAL CURRENT LIABILITIES 581,522
LONG-TERM DEBT
Note payable to stockholder 9,920
Capital lease obligations 10,931
-----------
20,851
STOCKHOLDERS' DEFICIENCY
Preferred stock, 496,000,000 shares authorized;
none issued --
Series A cumulative convertible preferred stock,
no par value; 4,000,000 shares authorized;
231,100 shares issued and outstanding 186,950
Common stock, no par value, 80,000,000 shares
authorized; 8,020,388 shares issued and outstanding 4,384,676
Paid-in capital 6,000
Accumulated deficit (4,798,524)
-----------
(220,898)
-----------
$ 381,475
===========
The accompanying notes are an integral part of these financial statements.
F-2
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Years Ended June 30, 2003 and 2002
2003 2002
----------- -----------
NET SALES $ 1,645,759 $ 1,358,278
COST OF SALES 363,819 262,639
----------- -----------
GROSS PROFIT 1,281,940 1,095,639
OPERATING EXPENSES
Salaries and benefits 560,073 456,720
Selling, general and administrat 648,409 740,294
----------- -----------
1,208,482 1,197,014
----------- -----------
INCOME (LOSS) FROM OPERATIONS 73,458 (101,375)
OTHER INCOME (EXPENSE)
Other income 80 446
Interest income 426 580
Interest expense (41,958) (37,562)
----------- -----------
(41,452) (36,536)
----------- -----------
INCOME (LOSS) BEFORE INCOME TAXES 32,006 (137,911)
INCOME TAX EXPENSE
Before loss carryforwards 8,238 --
Current benefit of loss carryforwards (8,238) --
----------- -----------
-- --
----------- -----------
NET INCOME (LOSS) 32,006 (137,911)
Dividend requirements on preferred stock 6,140 (28,860)
----------- -----------
Income (loss) applicable to common stock 38,146 $ (166,771)
=========== ===========
Basic and diluted net income (loss) per common share $ -- $ (0.02)
=========== ===========
Weighted average number of common
shares outstanding, basic and diluted 7,907,647 7,815,973
=========== ===========
The accompanying notes are an integral part of these financial statements.
F-3
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY
Years Ended June 30, 2003 and 2002
Preferred Stock Common Stock
------------------------ ----------------------- Paid-in Accumulated
Shares Amount Shares Amount Capital Deficit Total
---------- ---------- ---------- ---------- ---------- ---------- ----------
Balance, June 30, 2001 288,600 $ 244,450 7,840,338 $4,262,414 $ -- $ (4,692,619)$ (185,755)
Net loss -- -- -- -- -- (137,911) (137,911)
---------- ---------- ---------- ---------- ---------- ---------- ----------
Balance, June 30, 2002 288,600 244,450 7,840,338 4,262,414 -- (4,830,530) (323,666)
Stock options issued for services -- -- -- -- 6,000 -- 6,000
Conversion of preferred stock to
common stock (57,500) (57,500) 57,500 57,500 -- -- --
Common stock issued for services -- -- 26,050 6,862 -- -- 6,862
Stock options exercised -- -- 96,500 57,900 -- -- 57,900
Net income -- -- -- -- -- 32,006 32,006
---------- ---------- ---------- ---------- ---------- ---------- ----------
Balance, June 30, 2003 231,100 $ 186,950 8,020,388 $4,384,676 $ 6,000 $(4,798,524) $ (220,898)
========== ========== ========== ========== ========== ========== ==========
The accompanying notes are an integral part of these financial statements.
F-4
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended June 30, 2003 and 2002
2,003 2,002
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss) $ 32,006 $(137,911)
Adjustments to reconcile net income (loss) to
net cash used by operating activities:
Depreciation 15,984 13,170
Allowance for doubtful accounts 12,000 8,000
Write off of uncollectible accounts 21,215 1,712
Accrued interest on certificate of deposit 0 459
Common stock issued for services 6,862 0
Stock options issued for services 6,000 0
Decrease (increase) in:
Accounts receivable (71,282) (49,882)
Inventory (39,219) (12,570)
Prepaid expenses 7,019 (16,141)
Other assets 0 676
Increase (decrease) in:
Excess of checks issued over bank balance (24,168) 24,168
Accounts payable (41,259) (21,124)
Accrued expenses 37,628 (27,868)
--------- ---------
NET CASH USED BY
OPERATING ACTIVITIES (37,214) (217,311)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposition of property and equipment 0 1,982
Purchase of property and equipment (1,222) (8,994)
--------- ---------
NET CASH USED BY
INVESTING ACTIVITIES (1,222) (7,012)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stockholder loan 33,000 183,487
Payments of capital lease obligations (5,416) --
Proceeds from long-term debt -- 25,000
Repayment of long-term debt (5,499) (3,263)
Proceeds from issuance of common stock 57,900 --
--------- ---------
NET CASH PROVIDED BY
FINANCING ACTIVITIES 79,985 205,224
--------- ---------
NET CHANGE IN CASH 41,549 (19,099)
CASH AT BEGINNING OF PERIOD -- 19,099
CASH AT END OF PERIOD $ 41,549 $ --
========= =========
SUPPLEMENTAL DISCLOSURES
Taxes Paid $ -- $ --
Interest Paid $ 41,958 $ 37,562
NONCASH TRANSACTIONS DISCLOSURE:
Conversion of Series A cumulative convertible
preferred stock to common stock $ 57,500 $ --
Common stock issued for services $ 6,862 $ --
Stock options issued for services $ 6,000 $ --
Purchase of property and equipment under
capital lease obligations $ 24,549 $ --
The accompanying notes are an integral part of these financial statements.
F-5
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Activity
-----------------
Procyon Corporation has two wholly-owned subsidiaries, Amerx Health Care Corp.
(Amerx) and Sirius Medical Supplies, Inc. (Sirius). Amerx manufactures and
markets wound and skin care products in the United States whereas Sirius markets
diabetic supplies primarily to Medicare patients in the United States.
Principles of Consolidation
---------------------------
The consolidated financial statements include the accounts of Procyon
Corporation and its wholly-owned subsidiaries, Amerx and Sirius. All material
intercompany accounts and transactions are eliminated.
Use of Estimates
----------------
The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities at the date of
the financial statements, and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
-------------------
Revenue is recognized upon the shipment of goods to customers and when title
passes to the customers. The Company does not have a written return policy with
its customers. Each return request is reviewed by management for approval.
Inventories
-----------
Inventories are valued at the lower of weighted average cost or market
determined by the first-in, first-out method.
Property and Equipment
----------------------
Property and equipment are stated at cost. Depreciation is computed on a
straight-line basis over the estimated useful life of 5 years. Leased equipment
are recorded at their fair market value at the beginning of the lease term and
are depreciated over the life of the equipment. Depreciation on leased equipment
is included in depreciation expense.
Cash and Cash Equivalents
-------------------------
For the purpose of the Statements of Cash Flows, the Company considers
cash-on-hand, demand deposits in banks and highly liquid investments purchased
with an original maturity of three months or less to be cash equivalents.
The Company has classified the certificates of deposits as restricted assets.
These certificates of deposits are collateral on a letter of credit issued at
the request of a vendor and therefore are not available for operations.
Concentrations of Credit Risk
-----------------------------
Financial instruments which potentially subject the Company to concentrations of
credit risk consist primarily of cash and cash equivalents. The Company
maintains its cash and cash equivalents in one financial institution. The
Federal Deposit Insurance Corporation (FDIC) insures cash and cash equivalents
deposited at a financial institution for up to $100,000. The Company did not
have any uninsured cash and cash equivalents at June 30, 2003.
Amerx grants credit to customers most of whom are national pharmaceutical
companies, nationwide drug stores and physicians. Amerx wholesales its products
to national pharmaceutical companies and nationwide drug stores at a sales term
of 2/10, net 30. Amerx does not have a written return policy with these
customers. Each return request is reviewed by management for approval. Sales to
physicians and patients are at retail and standard payment term is 30 days.
F-6
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
Sirius grants credit to physicians and patients who are eligible for Medicare
coverage. Sales are at standard payment term of 30 days.
Management deems that an allowance for doubtful accounts of $20,500 is adequate
based upon its review of its receivables and its collection experience.
Shipping and Handling Costs
---------------------------
Shipping and handling costs incurred were approximately $66,000 and $78,000 for
the years ended June 30, 2003 and 2002, respectively, and were included in
selling, general and administrative expenses.
Advertising and Marketing
-------------------------
In accordance with Statement of Position 93-7, "Reporting on Advertising Costs",
advertising costs are to be expensed except for direct-response advertising (1)
whose primary purpose is to elicit sales to customers who could be shown to have
responded specifically to the advertising and (2) that results in probable
future economic benefits. In order to determine whether such advertisements
generate probable future economic benefits, the Company must establish
historical patterns of responses to the direct-response advertising. Management
believes that there is insufficient history to evaluate the future economic
benefits from direct-response advertising. Therefore, all advertising costs
incurred are expensed. During the years ended June 30, 2003 and 2002,
approximately $288,000 and $367,000, respectively, of advertising and marketing
costs were included in selling, general and administrative expenses.
Income Taxes
------------
The Company accounts for income taxes under Statement of Financial Accounting
Standards No. 109, "Accounting for Income Taxes" ("SFAS 109"). SFAS 109 requires
the recognition of deferred tax assets and liabilities for the expected future
tax consequences of events that have been included in the financial statements
or tax returns. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statement and the tax
basis of assets and liabilities using enacted tax provisions currently in effect
and rates applicable to the periods in which the differences are expected to
affect taxable income.
Net Loss Per Share
------------------
Net loss per share is based on the weighted average number of shares outstanding
during each period presented. Outstanding stock rights are included as common
stock equivalents, when dilutive.
Fair Value of Financial Instruments
-----------------------------------
The carrying value of cash, accounts receivable, deposits, inventory, accounts
payable, and accrued expenses approximate fair value. Note payable to related
party is discussed in Note E.
Considerable judgement is required in interpreting market data to develop the
estimates of fair value, and, accordingly, the estimates are not necessarily
indicative of the amounts that the Company could realize in a current market
exchange.
Stock Based Compensation
------------------------
In December 1998, the Company adopted a 1998 Omnibus Stock Option Plan that
provides for the granting of equity- based incentive and other awards to
employees and directors of the Company, its subsidiaries and selected
consultants. The Plan is administered by the Compensation Committee of the Board
of Directors. Any employee, directors who are not employees of the Corporation
or a subsidiary, and consultants who are not employees or directors of the
Corporation are eligible to participate in the Plan. The maximum number of
shares of common stock issuable on exercise of options or other awards granted
under the Plan is 1,000,000. Non-qualified options granted must have an exercise
price not less than 85% of the fair market value of the underlying shares of
common stock. Incentive options must have an exercise price not less than 100%
of the fair market value of the underlying shares of common stock. The term of
the options cannot be more than ten years. Awards may be granted in the form of
restricted stock. Awards can also be granted in
F-7
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
the form of stock appreciation rights. A stock appreciation right entitles the
participant to receive from the Company an amount equal to the positive
difference between the fair market value of common stock on the date of exercise
of the stock appreciation right and the grant price. No stock appreciation
rights have been issued to date pending a resolution by the Board of Directors
on earning requirements.
Additional information with respect to the Plan's stock option activity is as
follows:
Weighted
Number of Average
Shares Exercise Price
------------ ----------------
Outstanding at June 30, 2001 300,000 $0.20
Granted -
Exercised -
Cancelled -
------------
Outstanding at June 30, 2002 300,000 $0.20
Granted 275,000 0.87
Exercised (96,500) 0.60
Expired (178,500) 1.02
------------
Outstanding at June 30, 2003 300,000 $0.20
============ =====
Options exercisable at June 30, 2002 300,000 $0.20
============ =====
Options exercisable at June 30, 2003 300,000 $0.20
============ =====
The following table summarizes information about stock options outstanding at
June 30, 2003:
Stock Options Outstanding
-----------------------------------------------------------
Weighted Average
Number of Remaining Weighted
Range of Shares Contractual Life Average
Exercise Prices Outstanding In Years Exercise Price
------------------ -------------- --------------------- ----------------
$0.15 - $0.20 65,000 7.39 $0.16
$0.20 - $0.25 235,000 6.51 $0.21
--------------
300,000 6.70 $0.20
============== ==== =====
The Company has elected to follow APB Opinion No. 25 "Accounting for Stock
Issued to Employees" in accounting for its employee stock options and has
adopted the disclosure provisions of Statement of Financial Accounting Standards
No. 148, "Accounting for Stock-Based Compensation -- Transition and Disclosure,
an amendment of FASB Statement No. 123." Under APB No. 25, when the exercise
price of the employee stock options equals or exceeds the market price of the
underlying stock on the date of grant, no compensation expense is recognized.
Accordingly, no compensation expense has been recognized in the consolidated
financial statements in connection with employee stock option grants.
The following table illustrates the effect on net income (loss) and earnings
(loss) per share had the Company applied the fair value recognition provisions
of Statement of Financial Accounting Standards No. 123, "Accounting for
Stock-Based Compensation," to stock-based employee compensation.
2003 2002
---------- ----------
Net income (loss) applicable to common stock:
As reported $ 32,006 $ (137,911)
Pro forma adjustment for compensation - -
---------- ----------
Pro forma $ 32,006 $ (137,911)
========== ==========
Basic and diluted income (loss) per common share:
As reported $ - $ (0.40)
Pro forma $ - $ (0.40)
F-8
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
There were no options issued during fiscal year ended June 30, 2002. Th
weighted average estimated fair value of stock options granted during the year
ended June 30, 2003 was $0.52. These amounts were determined using the Black-
Scholes option-pricing model, which values options based on the stock price at
the grant date, the expected dividend payments, and the risk-free interest rate
over the life of the option. The assumptions used in the Black-Scholes model
were as follows for stock options granted in the years ended June 30:
2003 2002
---------- ----------
Risk-free interest rate 1.09%
Expected volatility of common stock 513.04% There were no options
Dividend yield 0% granted during this
Expected life of options < 1 year fiscal year.
The Black-Scholes option valuation model was developed for estimating the fair
value of traded options that have no vesting restrictions and are fully
transferable. Because option valuation models require the use of subjective
assumptions, changes in these assumptions can materially affect the fair value
of the options. The Company's options do not have the characteristics of traded
options, therefore, the option valuation models do not necessarily provide a
reliable measure of the fair value of its options.
Equity instruments issued to non-employees in exchange for goods, fees and
services are accounted for under the fair value-based method of SFAS No. 123.
NOTE B - GOING CONCERN
As reflected in the accompanying financial statements, the Company has a deficit
in stockholders' equity of $220,898 at June 30, 2003. The Company has net income
of $32,006 for the fiscal year ended June 30, 2003 and incurred a net loss of
$137,911 for the year ended June 30, 2002. In addition, net cash used in
operations was $37,214 and $217,311 for the years ended June 30, 2003 and 2002,
respectively. Such operating cash deficiencies have been funded through the
Company's line of credit with its major shareholder.
The ability of the Company to continue as a going concern is dependent upon the
availability of funds through its majority stockholder and its ability to
generate sales to cover its operating costs. The Company has not borrowed funds
from its majority stockholder since the last quarter of the fiscal year ended
June 30, 2003 and has been able to cover its operating costs with sufficient
revenues. Sales for the two months subsequent to fiscal year ended June 30, 2003
were also sufficient to cover its operating costs. The financial statements do
not include any adjustments that might be necessary if the Company is unable to
continue as a going concern.
NOTE C - INVENTORIES
Inventories consisted of the following:
Finished Goods $ 32,262
Raw Materials 64,260
----------
$ 96,522
==========
NOTE D - PROPERTY AND EQUIPMENT
Property and equipment consisted of the following:
Owned Leased Total
---------- ---------- -----------
Office equipment $ 60,519 $ 25,365 $ 85,884
Furniture and fixtures 15,164 - 15,164
Production equipment 14,236 - 14,236
---------- ---------- -----------
89,919 25,365 115,284
Less accumulated depreciation (61,633) (4,522) (66,155)
---------- ---------- -----------
$ 28,286 $ 20,843 $ 49,129
========== ========== ===========
F-9
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE E - RELATED PARTY TRANSACTIONS
The majority shareholder and President of the Company has a $300,000,
due-on-demand line of credit with a financial institution, collateralized by his
personal residence. The line of credit is renewed annually. The majority
shareholder of the Company extended the line of credit to the Company in the
form of a note payable at 8% interest per annum. The note payable is due on
demand from the majority shareholder. At June 30, 2003, the majority shareholder
was owed $291,488 on the note. Interest expense for the years ended June 30,
2003 and 2002 were $14,133 and $10,970, respectively.
The Company has an unsecured note payable with one of its officers. The note
calls for monthly payments to the officer of approximately $683 at an interest
rate of 14% per annum. At June 30, 2003, the balance of the note was $16,239.
Interest expense for the years ended June 30, 2003 and 2002 were $2,635 and
$2,456 respectively. See NOTE G - LONG-TERM DEBT for additional disclosure.
NOTE F - COMMITMENTS AND CONTINGENCIES
Leases
------
The Company leases certain equipment under various capital and operating leases
expiring through year 2008. Certain capital leases contain bargain purchase
options at the end of the lease terms. The minimum lease payments due under the
lease agreements for fiscal years ended June 30 is as follow:
2004 $ 17,738
2005 15,885
2006 9,356
2007 1,515
2008 and thereafter 379
---------
$ 44,873
=========
The Company also leases its warehouse and office on a month-to-month basis. Rent
expense for the years ended June 30, 2003 and 2002, was approximately $50,000
and $48,000, respectively.
Purchase Commitments
--------------------
Sirius entered into a two-year contract with one of its suppliers in May 2002 to
purchase a minimum quantity of various diabetic supplies at a discounted price
and to maintain its shared market level. In accordance with the terms of the
contract, Sirius could be charged back the discount if Sirius did not purchase
the committed minimum quantity or maintain the required market share level in
the given contract year. For the year ended June 30, 2003, Sirius was informed
by the supplier that it did not meet the minimum purchase quantity and therefore
may be charged back the difference which approximates $3,200. The supplier
offered to either waive the charge back on the current contract or enter into a
new contract with Sirius which will require Sirius to pay the charge back and
commit to a higher minimum purchase quantity at a much reduced price. Management
believes either option will not adversely affect the Company and is currently
considering these two options.
In June 2003, Amerx entered into an agreement to purchase manufacturing
equipment at a cost of $16,000. A $4,000 deposit, which is reflected in the
accompanying financial statements as a prepaid expense, was paid upon the
signing of the contract and the remaining balance is payable in equal
installments 30, 60 and 90 days from such date. Title to the equipment will pass
to Amerx upon full payment of the contract price.
Open Letter of Credit
---------------------
The Company has letter of credit of $17,000 outstanding at June 30, 2003. The
letter of credit is maintained as collateral on the certificates of deposits.
The letter of credit was issued at the request of a vendor.
F-10
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE G - LONG-TERM DEBT
Long-term debt consists of a note payable to one of the Company's officers. The
note calls for monthly payments of approximately $683 at an interest rate of 14%
per annum. Maturities of long-term debt for the years ending June 30 are as
follows:
2004 $ 6,319
2005 7,264
2006 2,656
----------
16,239
Less: current portion (6,319)
----------
$ 9,920
==========
The Company leases certain equipment under various capital leases expiring
through year 2006. Certain capital leases contain bargain purchase options at
the end of the lease terms. The minimum lease payment due under the lease
agreements for fiscal years ended June 30 is as follow:
2004 $ 11,213
2005 9,350
2006 2,820
----------
Total minimum lease payments 23,383
Less: amount representing interest (4,250)
----------
Total obligations under capital leases 19,133
Less: current portion (8,202)
$ 10,931
==========
NOTE H - STOCKHOLDERS' DEFICIENCY
During January 1995, the Company's Board of Directors authorized the issuance of
up to 4,000,000 shares of Series A Cumulative Convertible Preferred Stock. The
preferred stockholders are entitled to receive, if declared by the board of
directors, quarterly dividends at an annual rate of $.10 per share of Series A
Cumulative Convertible Preferred Stock per annum. Dividends accrue without
interest and are cumulative from the date of issuance of the Series A Cumulative
Convertible Preferred Stock and are payable quarterly in arrears in cash or
publicly traded common stock when and if declared by the board of directors. As
of June 30, 2003, no dividends have been declared. Dividends in arrears on the
outstanding preferred shares total $141,511 or approximately $0.61 per share as
of June 30, 2003. The preferred stockholders have the right to convert each
share of Series A Cumulative Convertible Preferred Stock into one share of the
Company's common stock at any time without additional consideration. Each share
of Series A Cumulative Convertible Preferred Stock is subject to mandatory
conversion into one share of common stock of the Company, effective as of the
close of a public offering of the Company's common stock provided, however, that
the offering must provide a minimum of $1 million in gross proceeds to the
Company and the initial offering price of such common stock must be at least $1
per share. In addition to the rights described above, the holders of the Series
A Cumulative Convertible Preferred Stock have voting rights equal to the common
stockholders based upon the number of shares of common stock into which the
Series A Cumulative Convertible Preferred Stock is convertible. The Company is
obligated to reserve an adequate number of shares of its common stock to satisfy
the conversion of all of the outstanding Series A Cumulative Convertible
Preferred Stock.
F-11
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE I - EARNINGS (LOSS) PER SHARE
As required by FASB Statement No. 128, the following table sets forth the
computation of basic and diluted earnings (loss) per share:
Years Ended June 30,
--------------------------
2003 2002
----------- -----------
Numerator:
----------
Net income (loss) $ 32,006 $ (137,911)
Adjustment for basic earnings per share
Dividend requirements on preferred stock 6,140 (28,860)
----------- -----------
Numerator for basic earnings per share-
Net income (loss) available to common
stockholders $ 38,146 $ (166,771)
Effect of dilutive securities
Numerator for diluted earnings per share-
Net income (loss) available to common
stockholder $ 38,146 $ (166,771)
=========== ===========
Denominator:
------------
Denominator for basic earnings per share-
Weighted-average common shares 7,907,647 7,815,973
Effect of dilutive securities
Stock options -- --
Dilutive potential common shares -- --
----------- -----------
Denominator for dilutive earnings per share-
Adjusted weighted-average shares and
assumed conversions 7,907,647 7,815,973
=========== ===========
Basic and diluted income (loss) per share $ 0.00 $ (0.02)
=========== ===========
Weighted-average number of shares
outstanding used in computation:
Basic and diluted 7,907,647 7,815,973
=========== ===========
Unexercised options to purchase 300,000 shares of common stock for 2003 and 2002
were not included in the computation of diluted income (loss) per share because
the assumed conversion would be antidilutive.
NOTE J - INCOME TAXES AND AVAILABLE CARRYFORWARDS
The Company's deferred tax asset at June 30, 2003 consists primarily of the tax
benefit of net operating loss carryforwards amounting to approximately $988,000.
The Company has recorded a valuation allowance equal to 100 percent of the
deferred tax asset as the Company determined that it is more likely than not
that the deferred tax asset will be realized. The valuation allowance decreased
approximately $416,000 from June 30, 2002 to 2003. At June 30, 2003, for income
tax purposes, the Company had net operating loss carryforwards of approximately
$4,830,000 which expire on various dates through 2023.
Although the Company had consolidated net income for the year ended June 30,
2003, no provision of federal income taxes was provided due to available net
operating loss carryforwards. The provision for federal income taxes at
statutory rates is computed as follows:
F-12
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
2003 2002
--------- -------
Taxes at statutory 15% rate $ 8,238 $ -
Tax effect of:
Net operating loss benefits (8,238) -
$ - $ -
========= =======
NOTE K - CONCENTRATION OF RISK
The Company's manufacturing and packaging activities are performed at a
production facility owned and operated by a nonaffiliated pharmaceutical
manufacturer. At the present time, the manufacturer is the sole source of the
Company's wound care products. However, the Company has maintained a long-term
relationship with this manufacturer and does not expect a discontinuance of its
wound care products from the manufacturer in the near term.
Approximately 50% of Sirius's customers purchase their diabetic supplies from a
non-affiliated supplier that are distributed by the Company. The Company entered
into a contract with this supplier to purchase a minimum quantity of products at
a discount. (See NOTE F - COMMITMENTS AND CONTINGENCIES for disclosure) The
Company does not anticipate supply from this vendor will be lost in the near
future. In the event the contract is not renewed upon its expiration, the
Company could still purchase such products at a higher cost from this supplier
or negotiate with other suppliers.
NOTE L - SEGMENT INFORMATION
The Company operates in the following two business segments:
1. Sale of skin and wound care products - Amerx operates in the skin and wound
care products segment. The marketing of these products is targeted
primarily to diabetic patients who have difficulties providing proper care
and treatment of wounds due to their diabetic condition and podiatrists who
recommend the products to their patients.
2. Sale of diabetic supplies - Sirius provides meters, test strips, monitors,
syringes, etc. primarily to diabetic patients. The Company is then
reimbursed by Medicare and/or patients' secondary insurance.
Each separately managed segment offers different products requiring different
marketing and distribution strategies.
Segments Information
Wound Care Diabetic
June 30, Products Products Other Consolidated
------------ ----------- ----------- ---------- -----------
Revenues 2003 $ 1,322,763 $ 318,258 $ 4,738 $ 1,645,759
2002 1,167,651 171,036 19,591 1,358,278
Gross Profit 2003 1,141,846 139,821 273 1,281,940
2002 1,009,387 86,141 111 1,095,639
Identifiable Assets 2003 253,262 108,959 19,254 381,475
2002 152,749 75,453 - 228,202
Property and Equipment
Additions 2003 16,478 9,293 - 25,771
2002 8,994 - - 8,994
Depreciation 2003 13,143 1,384 1,457 15,984
2002 11,092 623 1,455 13,170
F-13
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
Geographical Information
The Company operates and sells its products to its customers within the United
States. All assets are located within the United States.
MOTE M - RECENT ACCOUNTING PRONOUNCEMENTS
In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with
Exit or Disposal Activities, which is effective for exit or disposal activities
initiated after December 31, 2002, with early application encouraged. This
statement requires a liability for a cost associated with an exit or disposal
activity to be recognized at fair value in the period in which the liability is
incurred, except for liabilities for one-time termination benefits requiring
future employee service, which is to be recognized ratably over the remaining
service period. The Company is currently evaluating the effects of the
recognition provision of SFAS No. 146, but does not expect the adoption to have
a material impact on its financial position or results of operations.
In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based
Compensation-Transition and Disclosure. This statement requires all entities
with stock-based employee compensation arrangements to provide additional
disclosures in their summary of significant accounting policies note. The
Company has adopted this Statement by disclosing its accounting for stock-based
compensation in the Summary of Significant Accounting Policies footnote.
In November 2002, the FASB issued FASB Interpretation No. 45, "Guarantor's
Accounting and Disclosure Requirements for Guarantees, Including Indirect
Guarantees of Indebtedness of Others." FIN No. 45 requires that upon issuance of
a guarantee, a guarantor must recognize a liability for the fair value of an
obligation assumed under a guarantee. FIN No. 45 also requires additional
disclosures by a guarantor in its interim and annual financial statements about
the obligations associated with guarantees issued. The recognition provisions of
FIN No. 45 are effective for any guarantees issued or modified after December
31, 2002. The disclosure requirements are effective for financial statements of
interim or annual periods ending after December 15, 2002. The adoption of the
disclosure requirements of FIN No. 45 did not have a material impact on the
Company's financial position or results of operations. The Company is currently
evaluating the effects of the recognition provision of FIN No. 45, but does not
expect the adoption to have a material impact on its financial position or
results of operations.
In April 2003, the FASB issued SFAS No. 149, "Amendments of Statement 133 on
Derivative Instruments and Hedging Activities" ("SFAS No. 149"). SFAS No. 149
serves as an amendment and clarifies financial accounting and reporting for
derivative instruments, including derivative instruments embedded in other
contracts and for hedging activities under SFAS No. 133, "Accounting for
Derivative Instruments and Hedging Activities." SFAS No. 149 is to be applied
prospectively to all contracts entered into or modified after June 30, 2003 and
for hedging relationships designated after June 30, 2003. However, the
provisions of this statement that relate to "SFAS 133 Implementation Issues,"
which have been effective for fiscal quarters beginning prior to June 15, 2003,
continue to be applied in accordance with their respective effective dates. The
Company is currently evaluating the effects of the provisions of SFAS No. 149,
but does not expect the adoption to have a material impact on its financial
position or results of operations.
In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial
Instruments with Characteristics of Both Liabilities and Equity" ("SFAS No.
150"). SFAS No. 150 establishes standards for how an issuer classifies and
measures certain financial instruments with characteristics of both liabilities
and equity. SFAS No. 150 requires that an issuer classify a financial instrument
that is within its scope as a liability (or an asset in some circumstances). The
requirements of this statement apply to issuers' classification and measurement
of freestanding financial instruments, including those that comprise more than
one option or forward contract. SFAS No. 150 is effective for financial
instruments entered into or modified after May 31, 2003, and otherwise is
effective at the beginning of the first interim period beginning after June 15,
2003. The Company is currently evaluating the effects of the provisions of SFAS
No. 150, but does not expect the adoption to have a material impact on its
financial position or results of operations.
F-14